Evidence map›Paper›PMID 19723832›Full record

ArticleInnate immunity2010

Lactoferrin decreases LPS-induced mitochondrial dysfunction in cultured cells and in animal endotoxemia model.

Marian L Kruzel, Jeffrey K Actor, Zsolt Radak, Attila Bacsi, Alfredo Saavedra-Molina, Istvan Boldogh

Open access · greenAbstract read
In one paragraph

Article in Innate immunity, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Article
  3. Modulation of TDM-induced granuloma pathology by human lactoferrin: a persistent effect in mice.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2023
    Article
  4. Lactoferrin as a Human Genome "Guardian"-An Overall Point of View.International journal of molecular sciences · 2022
    Review
  5. The Lactoferrin Phenomenon-A Miracle Molecule.Molecules (Basel, Switzerland) · 2022
    Review
  6. Kidney protective potential of lactoferrin: pharmacological insights and therapeutic advances.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2022
    Review
  7. Review
  8. Review
  9. Review
  10. Lactoferrin as potential preventative and adjunct treatment for COVID-19.International journal of antimicrobial agents · 2020
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Marian L KruzelDepartment of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston Medical School, Texas, USA.
Jeffrey K Actor
Zsolt Radak
Attila Bacsi
Alfredo Saavedra-Molina
Istvan Boldogh
The University of Texas Health Science Center at Houston · USSemmelweis University · HUThe University of Texas Medical Branch at Galveston · USUniversidad Michoacana de San Nicolás de Hidalgo · MXUniversity of Debrecen · HU

Funding

Virus, Tissue Culture and ImmunoassayP01AI062885 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI GAROFALO, ROBERTO P · 2005 to 2022
$23.9M
Synthetic Organic Chemistry CoreP30ES006676 · NIEHS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ELFERINK, CORNELIS JOHAN · 1995 to 2017
$21.7M
OXIDATIVE STRESS,REPAIR OF OXIDIZED GUANINES IN AGED CELLSP01AG021830 · NIA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI PAPACONSTANTINOU, JOHN NMN · 2004 to 2010
$6.4M
Lactoferrin for Immunomodulation of Systemic Inflammatory Response SyndromeR41GM079810 · NIGMS · PHARMAREVIEW CORPORATION · PI ACTOR, JEFFREY K · 2007 to 2008
$298k
NIAID NIH HHS AI062885-01NIAID NIH HHS P01 AI062885NIA NIH HHS P01 AG021830NIEHS NIH HHS P30 ES006676NIGMS NIH HHS 1R41GM079810-01NIGMS NIH HHS R41 GM079810PHS HHS EOS 0 06677
6 · The paper itself

Abstract

Lactoferrin is a non-heme iron-binding glycoprotein, produced by mucosal epithelial cells and granulocytes in most mammalian species. It is involved in regulation of immune responses, possesses anti-oxidant, anti-carcinogenic, anti-inflammatory properties, and provides protection against various microbial infections. In addition, lactoferrin has been implicated in protection against the development of insult-induced systemic inflammatory response syndrome (SIRS) and its progression into septic conditions in vivo. Here we show a potential mechanism by which lactoferrin lessens oxidative insult at the cellular and tissue levels after lipopolysaccharide (LPS) exposure. Lactoferrin pretreatment of cells decreased LPS-mediated oxidative insults in a dose-dependent manner. Lipopolysaccharide-induced oxidative burst was found to be of mitochondrial origin, and release of reactive oxygen species (ROS) was localized to the respiratory complex III. Importantly, lactoferrin nearly abolished LPS-induced increases in mitochondrial ROS generation and the accumulation of oxidative damage in the DNA. In vivo, pretreatment of experimental animals with lactoferrin significantly (P<0.05) lowered LPS-induced mitochondrial dysfunction as shown by both decreased release of H(2)O(2) and DNA damage in the mitochondria. In contrast, deferoxamine, an iron chelating compound, provided only partial protection in LPS-treated animals. Together, these data suggest that lactoferrin protects against oxidative insult at the mitochondrial level, and indicate a potential utility of lactoferrin in prevention and treatment of SIRS.

Indexed as

AnimalsDeferoxamineDisease Models, AnimalDNA DamageDose-Response Relationship, ImmunologicElectron Transport Complex IIIEndotoxemiaEpithelial CellsHumansHydrogen PeroxideLactoferrinLipopolysaccharidesMiceMice, Inbred BALB CMitochondriaMonocytesDeferoxamineElectron Transport Complex IIIHydrogen PeroxideLactoferrinLipopolysaccharidesReactive Oxygen SpeciesSiderophores

Identifiers

PMID19723832
PMCPMC3030479
OpenAlexW1978667507

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.